BRIEF-Gilead Sciences Exercises Option To License Assembly Biosciences’ Helicase-Primase Inhibitor Programs For Recurrent Genital Herpes

Reuters
Dec 22, 2025
BRIEF-<a href="https://laohu8.com/S/GILD">Gilead</a> Sciences Exercises Option To License <a href="https://laohu8.com/S/ASMB">Assembly Biosciences</a>’ Helicase-Primase Inhibitor Programs For Recurrent Genital Herpes

Dec 22 (Reuters) - Assembly Biosciences Inc ASMB.O:

  • GILEAD SCIENCES EXERCISES OPTION TO LICENSE ASSEMBLY BIOSCIENCES’ HELICASE-PRIMASE INHIBITOR PROGRAMS FOR RECURRENT GENITAL HERPES

  • GILEAD - ASSEMBLY BIO TO RECEIVE $35 MILLION FOR GILEAD'S HSV OPTION

Source text: ID:nBw9s5GZKa

Further company coverage: ASMB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10